Reviva Pharmaceuticals Presents Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Reviva Pharmaceuticals (NASDAQ:RVPH) presented promising clinical pharmacology and safety studies data on brilaroxazine at the ASPET 2023 annual meeting. Brilaroxazine is currently in phase 3 clinical trials for schizophrenia, with topline data expected mid-year.
May 22, 2023 | 10:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Reviva Pharmaceuticals presented positive data on brilaroxazine at ASPET 2023, which is in phase 3 clinical trials for schizophrenia. Topline data is expected mid-year.
The presentation of promising data on brilaroxazine at the ASPET 2023 annual meeting indicates progress in the development of the drug. As it is currently in phase 3 clinical trials for schizophrenia, positive results could lead to potential FDA approval and commercialization, positively impacting Reviva Pharmaceuticals' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100